Company / Accounts Receivable
Twist Bioscience Corp Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$57.0M
FY2025
5-year range
$28.5M / $57.0M
FY2021-FY2025
Trend
+63.4%
vs FY2024
Sector context
#68 of 115
Health Care
What the data says
At $57M, Twist Bioscience Corp's accounts receivable ranks #68 of 115 in the Health Care sector. Improved from $44M to $57M over the past 2 years.
Based on SEC 10-K filings.
$57M in FY2025 with a 5-year CAGR of +16.7%.
Improved from $44M to $57M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +12.3%
- 5-Year CAGR
- +16.7%
- 10-Year CAGR
- -
Sector benchmark
#68 of 115 in Health CareTop 59% of 115This company $57.0M Sector average $1.1B
▼
-94.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.7%, indicating consistent growth.
- In FY2025, accounts receivable increased 63.4% year-over-year.
- Ranks #68 out of 115 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $57.0M | +63.4% |
| FY2024 | $34.9M | -20.8% |
| FY2023 | $44.1M | +9.4% |
| FY2022 | $40.3M | +41.1% |
| FY2021 | $28.5M | +8.2% |
| FY2020 | $26.4M | +117.9% |
| FY2019 | $12.1M | +123.4% |
| FY2018 | $5.4M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026